Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.
Info & Links
CEO
Carole S. Ben-Maimon
Headquarters
THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD, PA 19004, UNITED STATES
Larimar Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
121.33M
Enterprise Value
88.11M
Enterprise Value/EBITDA(ttm)
-0.92
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
1.05
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-35.87%
Return on Invested Capital(ttm)
-41.17%
Return on Assets(ttm)
-32.37%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-95.83M
Net Income Available to Common(ttm)
-80.60M
Diluted EPS(ttm)
-1.15
Share Statistics
Beta (5Y Monthly)
0.91
52-Week Change
-73.01%
S&P 500 52-Week Change
5.42%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
64.03M
Dividend Yield
0.00%
Float4
61.57M
% Held by Insiders
3.50%
% Held by Institutions
91.92%
Balance Sheet
Total Cash(mrq)
183.45M
Total Cash Per Share(mrq)
2.87
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
8.02%
Quick Ratio(mrq)
13.10%
Book Value Per Share(mrq)
2.69
Cash Flow
Operating Cash Flow Per Share(ytd)
-1.16
Free Cash Flow(ytd)
-71.28M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.